Adaptilens
Latest round
- Series A
Last raised
- Apr 2024
Total raised
- $19M
Investors
- 4
About Adaptilens
Founded in 2019, and based in Massachusetts, US, Adaptilens, LLC operates as a developer of an intraocular lens that is injected into the patient's eyes. The company was founded by its CEO, Liane Clamen. Adaptilens researches and develops accommodating intraocular lenses (A-IOL) for cataract patients that restore their eye's ability to focus at multiple distances, thus reducing the need for glasses or contact lenses. The company’s pre-clinical product will mimic the natural human lens, allowing patients to see clearly at near, far, and intermediate distances.
Who invested in Adaptilens
4 investors across 2 rounds
See all investors in Adaptilens
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Adaptilens
Who invested in Adaptilens?
Adaptilens has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Adaptilens raised?
Adaptilens has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Adaptilens last raise money?
Adaptilens's most recent round on record is a Series A, in Apr 2024.
What does Adaptilens do?
Founded in 2019, and based in Massachusetts, US, Adaptilens, LLC operates as a developer of an intraocular lens that is injected into the patient's eyes.
Where is Adaptilens headquartered?
Adaptilens is headquartered in Boston, US.
Which VCs invest in companies like Adaptilens?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back healthcare specialists companies at Adaptilens's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series A
Raising like Adaptilens? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.